Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis <scp>C virus</scp> registry in Taiwan

Real‐world efficacy and safety of universal 8‐week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre‐end‐stage renal disease: Insights from a nationwide hepatisis <scp>C virus</scp> registry in Taiwan is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 4 citations, 2025 year and diamond oa status.